Literature DB >> 7397060

Acute cardiac failure during treatment with digitoxin--an interaction with rifampicin.

G Boman, K Eliasson, I Odar-Cederlöf.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7397060      PMCID： PMC1430022          DOI： 10.1111/j.1365-2125.1980.tb00507.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  Interaction of chronic daily warfarin therapy and rifampin.

Authors:  R A O'Reilly
Journal:  Ann Intern Med       Date:  1975-10       Impact factor: 25.391

2.  [Effects of rifampicin on the menstrual cycle and on oestrogen excretion in patients taking oral contraceptives].

Authors:  L Nocke-Finck; H Breuer; D Reimers
Journal:  Dtsch Med Wochenschr       Date:  1973-08-11       Impact factor: 0.628

3.  [The effects of antituberculosis drugs on the pharmacokinetics of digitoxin (author's transl)].

Authors:  U Peters; T U Hausamen; F Grosse-Brockhoff
Journal:  Dtsch Med Wochenschr       Date:  1974-11-22       Impact factor: 0.628

4.  Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid.

Authors:  G Boman
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

5.  [Rimactan (rifampicin) and anticoagulant therapy].

Authors:  F Michot; M Bürgi; J Büttner
Journal:  Schweiz Med Wochenschr       Date:  1970-03-28

6.  Pharmacokinetic interactions with rifampicin.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447
  6 in total
  7 in total

Review 1.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Pharmacokinetic drug interactions with rifampicin.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

3.  Effect of rifampicin treatment on the kinetics of mexiletine.

Authors:  P J Pentikäinen; I H Koivula; H A Hiltunen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 4.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 5.  Cardiac glycosides. Drug interactions of clinical significance.

Authors:  B Magnani; P L Malini
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

Review 6.  Clinical pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

7.  Influence of rifampicin and isoniazid on the kinetics of phenytoin.

Authors:  L Kay; J P Kampmann; T L Svendsen; B Vergman; J E Hansen; L Skovsted; M Kristensen
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.